CONNECT WITH US
AI & Deeptech

AI & Deeptech

Accelerating software delivery with agentic QA automation using Amazon Nova Act – Part 3

AWS Machine Learning logo

Published on

Add as a preferred source on Google
Accelerating software delivery with agentic QA automation using Amazon Nova Act – Part 3

As quality assurance (QA) automation adoption grows inside an organization, a new problem appears that has nothing to do with writing tests. A platform team stands up test automation, then a second team wants to join, then a dozen more. Soon hundreds of test cases belong to different products and squads, and everyone can see everyone else’s tests. No one can answer a basic question at a glance: is this application’s test coverage healthy right now? Test authoring stops being the bottleneck. Organizing tests and controlling who can touch them becomes the work.

A second, related question follows close behind: who owns this application and its tests, and who is accountable when coverage slips? Without a clear owner, health problems have no one to land on.

In the first post, we introduced QA Studio, a reference solution built with Amazon Nova Act. Teams use it to define tests in natural language and run them through AI-powered visual navigation. In the second post, we added test suites and a CLI for batch regression testing in continuous integration and continuous delivery (CI/CD) pipelines. In this post, we cover two capabilities that help QA Studio scale across an organization. The first, applications, organizes tests and reports health metrics. The second, team-based user management, controls who can see and change what.

An application in QA Studio represents the system under test: a website, a web app, a service front end. It’s the container that gives a collection of tests, a home, and an owner.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.